

Diabetic Innovator Announces New Injection Aid

SOUTHAMPTON, Mass., Nov. 1, 20xx

When faced with the certainty of daily insulin injections, innovator Chris Hillios knew he had to design a device that would help him overcome his injection anxiety. Through his determination and innovative spirit, Confidisc (TM) was developed.

Confidisc is an aid for injecting, by syringe or pen, insulin or like medications. It can be used by the patient or by a caregiver. "It is truly amazing that a simple device like Confidisc can make such a huge difference in one's life. Our testing has shown that Confidisc not only reduced pain perception, it clearly reduced injection anxiety," said Chris Hillios. "Users focus on the disk rather than the needle." With Confidisc's help, patients' lab results are now better than ever.

Confidisc enables users' access to a larger range of injection sites, allowing better injection rotation. It provides added stability in both filling the syringe and during injection. Its simple form is easy to use, convenient and cost-effective. Confidisc may be manufactured as a reusable attachment product and/or as a permanently fixed part of a hypodermic syringe. As a new hypodermic syringe, Confidisc also helps to deter illegal intravenous drug use.

More than 18 million Americans are living with type 2 diabetes. Many suffer from injection anxiety. Fear of injection can lead to improper treatment and poor control. "Having first-hand knowledge of the problems associated with home injections, it is our belief that this product will be of enormous benefit to the ever-growing diabetic population. Confidisc provides the confidence I need. I will no longer inject without it," said Hillios.

Confidisc was well-received by a review of Endocrinologist, Diabetic Educators and Nurse Practitioners. They look forward to having it available for their patients. It is sure to be a beneficial, simple, and affordable product for everyone facing daily injections. "Diabetes was our primary concern. However, we can now see that as the self-injectable market grows, the uses for Confidisc also grow," said Hillios.

Contact:

Chris Hillios

###